Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$239.62
▼ $5.56 (-2.3%)
Market data updated: 09/19 12:11 PM
Fundamentals updated: 09/19/2026
News analyzed: 09/19/2026
Market Cap
$36.18B
Day Range
$236.42 - $249.20
52-Week Range
$88.00 - $250.06
Beta
—
Next Earnings
28.10.2026
Support
$178.88
Resistance
$250.06
ILMN is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+132.6% (1Y)
Strengths: 20/29 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟢 Bullish
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 170.9%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: $87.22 vs. price $239.62 (-63.6%)
Fair Value
Signal tension
Growth scores strong (68/100), but fair-value analysis scores this stock as relatively expensive (33/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
Illumina (ILMN) carries a moderate investor score of 65, reflecting a blend of strong profitability and growth metrics tempered by valuation and risk concerns. The fundamentals are robust, with gross, operating, and net margins all above 18% and a return on equity of 31.2%, indicating efficient capital use. Earnings per share, free cash flow, and net income have surged over 150% year‑over‑year, underscoring powerful bottom‑line expansion despite a slight revenue decline of 0.7% last year. Technical signals are mixed: the price sits above both its 50‑day and 200‑day averages and the RSI is in a healthy 58.1 range, yet the MACD histogram is negative, hinting at waning momentum. Valuation appears stretched, as the estimated fair value of $87.22 is roughly 60% below the current price of $215.81, and a P/E of 39.6 further signals premium pricing. Risk metrics show notable volatility, with an ATR of 4.1% of price and a Calmar ratio of 0.21, reflecting a sizable drawdown relative to returns. News sentiment is largely positive, boosting confidence, but the overall risk‑adjusted picture remains cautious. Consequently, the overall score balances the impressive earnings growth and profitability against the high market price, moderate technical momentum, and elevated risk profile.
Price is above both the 50‑day and 200‑day moving averages, RSI sits at 58.1, %K is 63.9, but the MACD histogram is negative, indicating falling momentum.
Technical indicators gauge short‑term price trends and volatility, affecting trading risk.
Gross margin is 66.1%, operating margin 18.6%, net margin 19.6%, with ROE at 31.2% and ROA at 12.8%, all signaling strong profitability.
Strong fundamentals support earnings stability and capacity to generate cash.
EPS grew 170.9%, free cash flow 31.3%, and net income 169.5%, while revenue fell 0.7% over the last year.
High earnings growth shows profitability expansion, but weak top‑line growth may limit long‑term sustainability.
Estimated fair value is $87.22 versus a market price of $215.81, a 59.6% premium; P/E is 39.6 and NAV per share $8.97.
Valuation gaps suggest the stock may be overvalued relative to intrinsic estimates.
News sentiment scores are high (86) with several positive pieces, balanced by a few neutral and one negative article.
Media coverage influences investor perception and can affect price momentum.
Operating margin is stable or improving over time, yielding a quality score of 58.
Consistent margins indicate operational stability, though the middling score signals room for improvement.
ATR is 4.1% of price, current ratio 2.08, and Calmar ratio 0.21 (high drawdown of 54.8%).
Risk metrics highlight volatility and downside potential, impacting risk‑adjusted returns.
StockIQ conclusion
Illumina showcases strong profitability, impressive earnings and cash‑flow growth, and solid technical positioning above key averages. However, the market price appears substantially overvalued, revenue growth is flat, and risk indicators point to high volatility and potential drawdowns. These mixed signals produce a moderate overall investor score, highlighting both the company's operational strengths and the caution warranted by its valuation and risk profile.
Written automatically from the computed data shown on this page only — not investment advice.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
70
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
1d ago · $245.18
Evidence: FOMO score jumped from 28 to 67 day-over-day
What happened after
Still awaiting outcome
8d ago · $201.27
Evidence: Euphoria score crossed 55 (now 59)
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🕰️ StockIQ Time Machine
What did StockIQ know — and when? Pick a date from the real accumulated history.
As of August 26, 2026
Then
69
$224.99
Now
70
$239.62
What happened since
Signals detected by this date
No signals detected by this date
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
68
Quality
58
Value
33
Momentum
88
Risk
40
Sentiment
100
Fundamental
76
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of **Illumina, Inc.** has primarily focused on its inclusion in the **S&P 500 index** as part of the September 2026 rebalance, alongside companies like Bloom Energy and Everpure. The news highlights Illumina’s growing prominence in the genomics and multiomics sectors, where its technologies are positioned to benefit from expanding markets—such as spatial omics—driven by advancements in diagnostics, precision medicine, and large-scale biological data analysis.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Illumina, Inc.. News trend score: 100. Reason: 14 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
76
🎯 Conviction (vs. Emotion)
42
Investors appear highly excited (76), but evidence of strong fundamental conviction is comparatively weak (42).
Psychology
83
Fundamentals
76
Technical
88
Valuation
33
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, sentiment, and valuation keep confirming each other upward while the actual fundamentals deteriorate.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+48%
Market Narrative
95
Fundamental Reality
42
Narrative Gap
+53
🧠 StockIQ Psychologist
The market’s dominant euphoric state for ILMN is driven by extreme valuation disconnects (+142% DCF) and narrative dominance (100/100 sentiment), despite weak momentum and peer underperformance. Overconfidence and confirmation bias reinforce this, as traders prioritize growth narratives over diverging price action. The key tension lies in whether fundamentals (stagnant revenue) or valuation (142% premium) will anchor behavior next. The narrative gap (+33) suggests traders remain locked into optimistic expectations, but the lack of momentum signals may limit further euphoric rallies. The open question: will traders pivot from narrative-driven euphoria to valuation reality?
Updated: 09/09/2026, 05:11 AM
What could change this?
👥 What the crowd believes
"Illumina and Everpure also join the S&P 500 in the September rebalance"
"Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine"
"Illumina (ILMN) stock is up 64% post-GRAIL spin-off"
🧠 Market Brain events driving this
📈 14D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Peter Lynch — 79/100
🔴 Weakest match
Samuel Armstrong Nelson — 7/100
🗣️ Why do they disagree?
This stock sparks a sharp divide between growth-oriented methodologies and more conservative or market-savvy frameworks. Peter Lynch, Thorstein Veblen, and Jesse Livermore all see strong potential, with Lynch calling it a ‘growth candidate’ and Veblen and Livermore aligning with its upward momentum—suggesting their models prioritize upward trends and future earnings power. In contrast, the majority of traditional value investors—like Benjamin Graham (both Defensive and Enterprising), Edgar Lawrence Smith, and Samuel Nelson—reject it outright, flagging instability, overvaluation, or cyclical risks. Even mid-tier approaches like Philip Fisher and Walter Bagehot, while not dismissive, acknowledge it lacks the exceptional quality or liquidity they’d demand. The divide underscores a fundamental tension: growth hunters see untapped upside, while value and cycle-aware investors view it as either overpriced or vulnerable to market whims.
Peter Lynch
One Up on Wall Street (1989)
🟢 79
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟢 79
Positive trend — the price action Livermore looked for
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 71
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 66
Adequate but not exceptional liquidity
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 63
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 52
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 45
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 42
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 38
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 31
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 30
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 28
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🔴 14
Pattern consistent with a crowd delusion Mackay would flag
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 13
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 13
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 7
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (10 bullish · 1 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
66.1%
Operating Margin
18.6%
Net Margin
19.6%
EBITDA Margin
24.8%
ROE
31.2%
ROA
12.8%
ROIC
—
EPS
$5.47
Cash
$1.42B
Total Debt
—
Current Ratio
2.08
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$239.62
Estimated Fair Value (DCF)
$87.22
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-63.6%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
-0.8%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | -0.8% | $923.82M | $847.54M |
| 2 | 0.0% | $924.26M | $777.93M |
| 3 | 0.9% | $932.25M | $719.87M |
| 4 | 1.7% | $947.93M | $671.54M |
| 5 | 2.5% | $971.63M | $631.49M |
Base FCF (last actual year)
$931.00M
Terminal Value
$15.32B
Present Value of Terminal Value
$9.96B
Enterprise Value
$13.61B
Net Debt
$0
Equity Value
$13.61B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$17.46
Tangible Book Value per Share (Tangible NAV)
$8.97
Sentiment based on basic keywords (not AI) — 14 positive, 5 neutral, 1 negative out of the last 20 articles.
Yahoo · 18.9.2026
Yahoo · 18.9.2026
Benzinga · 18.9.2026
Yahoo · 17.9.2026
Yahoo · 16.9.2026
Benzinga · 16.9.2026
Benzinga · 16.9.2026
Yahoo · 16.9.2026
Benzinga · 15.9.2026
Benzinga · 11.9.2026
Yahoo · 10.9.2026
GlobeNewswire · 10.9.2026
Benzinga · 10.9.2026
Yahoo · 9.9.2026
Bloomberg · 9.9.2026
Yahoo · 9.9.2026
Yahoo · 9.9.2026
Barchart · 9.9.2026
Yahoo · 9.9.2026
Yahoo · 9.9.2026
Illumina, Inc. (ILMN) currently has a StockIQ AI score of 70/100, rated "Strong". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
ILMN currently scores 70/100 (Strong) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, ILMN's estimated fair value is $87.22, which is 63.6% below the current price of $239.62. This is one valuation model among several signals in the fair-value category, not a price target.
ILMN's technical score is 88/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 170.9%; Free cash flow growth: 31.3%; Net income growth: 169.5%.
Based on the real signals StockIQ computed: Estimated fair value: $87.22 vs. price $239.62 (-63.6%); ATR: 4.3% of price; Calmar: 0.38 (3y annualized return 20.6% / max drawdown 54.7%).
StockIQ has no recorded dividend payment history for ILMN.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 20 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Coletti Julie Ann | Grant/Award from Employer | 8.9.2026 | 5,307 | +5,307 | — |
| Coletti Julie Ann | Grant/Award from Employer | 8.9.2026 | 14,214 | +14,214 | — |
| Coletti Julie Ann | Grant/Award from Employer | 8.9.2026 | 5,307 | +5,307 | — |
| Coletti Julie Ann | Grant/Award from Employer | 8.9.2026 | 4,549 | +4,549 | — |
| Barnard Steven | Tax Withholding in Shares | 5.9.2026 | 408 | -408 | $211.06 |
| Meister Keith A. | Open Market Sale | 4.9.2026 | 7,500 | -7,500 | $217.28 |
| Meister Keith A. | Open Market Sale | 4.9.2026 | 11,351 | -11,351 | $219.18 |
| Meister Keith A. | Open Market Sale | 4.9.2026 | 100,650 | -100,650 | $218.39 |
| Meister Keith A. | Open Market Sale | 3.9.2026 | 6,656 | -6,656 | $220.17 |
| Meister Keith A. | Open Market Sale | 3.9.2026 | 13,261 | -13,261 | $216.38 |
| Meister Keith A. | Open Market Sale | 3.9.2026 | 9,721 | -9,721 | $218.33 |
| Meister Keith A. | Open Market Sale | 3.9.2026 | 14,196 | -14,196 | $217.29 |
| Meister Keith A. | Open Market Sale | 3.9.2026 | 9,961 | -9,961 | $221.55 |
| Meister Keith A. | Open Market Sale | 3.9.2026 | 13,717 | -13,717 | $219.41 |
| Meister Keith A. | Open Market Sale | 3.9.2026 | 8,439 | -8,439 | $215.20 |
| Meister Keith A. | Open Market Sale | 2.9.2026 | 10,620 | -10,620 | $213.73 |
| Meister Keith A. | Open Market Sale | 2.9.2026 | 57,488 | -57,488 | $213.20 |
| Meister Keith A. | Open Market Sale | 27.8.2026 | 1,167,416 | -4,873 | $226.74 |
| Meister Keith A. | Open Market Sale | 27.8.2026 | 1,071,754 | -16,990 | $229.72 |
| Meister Keith A. | Open Market Sale | 27.8.2026 | 1,043,315 | -28,439 | $230.54 |
| Meister Keith A. | Open Market Sale | 27.8.2026 | 1,088,744 | -24,363 | $228.64 |
| Meister Keith A. | Open Market Sale | 27.8.2026 | 1,113,107 | -54,309 | $227.67 |
| Meister Keith A. | Open Market Sale | 27.8.2026 | 1,033,910 | -9,405 | $231.23 |
| Meister Keith A. | Open Market Sale | 27.8.2026 | 28,439 | -28,439 | $230.54 |
| Meister Keith A. | Open Market Sale | 27.8.2026 | 16,990 | -16,990 | $229.72 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
9,720,715 shares short as of 2026-08-31 · vs. 8,056,689 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
67.8% of trading volume this week was short selling, vs. 75.4% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology